logo banner home news contact
nav

news

events

 

News

Return to News

Argos Therapeutics Appoints Jeffrey D. Abbey President and Chief Executive Officer


Durham, NC- March 2, 2010 — Argos Therapeutics announced today the appointment of Jeffrey D. Abbey as President and Chief Executive Officer. Mr. Abbey assumes leadership of Argos as John Bonfiglio, Ph.D., is leaving the company to pursue other business interests.

“I am excited to take on this role at a critical point in Argos´ growth. We are near completion of the Phase 2a study of AGS-004, our HIV candidate based on our Arcelis personalized immunotherapy platform, and plan to move this program into Phase 2b. We are continuing the Phase 2a study of AGS-003, also a product of our Arcelis technology, in combination with sunitinib, in renal cell carcinoma. Finally, Argos is continuing to advance our CD83 protein program for transplantation and immune-mediated disorders, preparing it for future clinical trials and engaging potential partners for this valuable asset,” commented Abbey. “We thank John for his many contributions to the Company and wish him the best.”

Jeffrey Abbey joined Argos in 2002 and has held positions of increasing seniority, most recently as Chief Business Officer. Mr. Abbey has extensive experience in structuring and negotiating licenses, joint ventures and other technology transfer agreements, as well as mergers, acquisitions and financing transactions. Mr. Abbey has been a partner at Eilenberg and Krause, a corporate law firm, where he acted as business counsel for a number of life sciences and other emerging technology companies. He also served as Vice President of Business Development and Finance for Internet Appliance Network, an information technology company. He holds an A.B. in Mathematical Economics from Brown University and received an M.B.A. and J.D. from the University of Virginia.

About Argos Therapeutics, Inc.
Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.argostherapeutics.com

Contacts:
Jennifer Conrad
MacDougall Biomedical Communications
(781) 235-3060

Jeff Abbey
Argos Therapeutics
(919) 287-6308

print friendly version

# # #